Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Last trade$3.51
Day change-$0.065 (-1.82%)
Day range$3.37 – $3.83
Volume1,964,205
Market cap$681M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$681.03M
Price / earnings
—
Price / book
4.77×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.08×
Profitability
Earnings per share
-$1.04
Return on assets
-79.46%
Return on equity
-139.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.35×
Current ratio
5.79×
Quick ratio
5.79×
Cash ratio
2.72×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$189.55M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ANNX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$10.87M
$10.64M
$10.27M
$7.6M
$7.32M
$7.57M
$9.23M
$9.13M
Research and development
$41.37M
$46.59M
$35.79M
$42.66M
$49.7M
$44.16M
$48.18M
$43.35M
Total operating expenses
$52.24M
$57.23M
$46.05M
$50.26M
$57.02M
$51.73M
$57.41M
$52.48M
Operating income
-$52.24M
-$57.23M
-$46.05M
-$50.26M
-$57.02M
-$51.73M
-$57.41M
-$52.48M
Interest expense
-$833K
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$51.22M
-$55.35M
-$44.14M
-$48.26M
-$54.92M
-$49.16M
-$54.36M
-$48.59M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$51.22M
-$55.35M
-$44.14M
-$48.26M
-$54.92M
-$49.16M
-$54.36M
-$48.59M
Net income attributable to common shareholders
-$51.22M
-$55.35M
-$44.14M
-$48.26M
-$54.92M
-$51.01M
-$54.36M
-$48.59M
EBITDA
-$51.71M
-$56.69M
-$45.51M
-$49.72M
-$56.47M
-$51.19M
-$56.87M
-$51.94M
Basic earnings per share
-$0.25
-$0.28
-$0.23
-$0.28
-$0.37
-$0.34
-$0.37
-$0.31
Diluted earnings per share
-$0.25
-$0.28
-$0.23
-$0.28
-$0.37
-$0.34
-$0.37
-$0.31
Recent news
Company coverage with links to the original publishers.
Annexon, Inc. (Nasdaq: ANNX) announced the grant of equity inducement awards to six new non-executive employees, consisting of options to purchase 1,270,000 shares of common stock at an exercise price of $3.60 per share with a ten-year term and four-year vesting schedule.
The GBS|CIDP Foundation International is launching the 'GBS: 110 Years, 110 Stories' campaign to mark 110 years since the discovery of Guillain-Barré syndrome. The campaign will feature 110 patient stories in short videos to raise awareness about GBS and CIDP, rare neurological disorders. The foundation has partnered with Annexon Biosciences to promote the campaign throughout 2026, highlighting the need for advancements in patient care.
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on targeted immunotherapies for neuroinflammatory diseases, announced that its President and CEO Douglas Love will present at the Bank of America Securities Health Care Conference on May 13, 2026. The company is advancing therapies targeting C1q-driven neuroinflammation, with ARCHER II pivotal Phase 3 data in geographic atrophy expected in Q4 2026.
Annexon, a biopharmaceutical company, granted a stock option to a new non-executive employee for 19,000 shares with a 4-year vesting schedule and an exercise price of $4.91 per share.
Annexon, a biopharmaceutical company, announced a public offering of 25,096,153 shares of common stock and pre-funded warrants, expecting to raise $75 million to support its neuroinflammation research platform.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.